BRPI0112986B8 - compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos - Google Patents

compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos

Info

Publication number
BRPI0112986B8
BRPI0112986B8 BRPI0112986A BR0112986A BRPI0112986B8 BR PI0112986 B8 BRPI0112986 B8 BR PI0112986B8 BR PI0112986 A BRPI0112986 A BR PI0112986A BR 0112986 A BR0112986 A BR 0112986A BR PI0112986 B8 BRPI0112986 B8 BR PI0112986B8
Authority
BR
Brazil
Prior art keywords
compounds
preparation
well
pharmaceutical compositions
azabicyclic
Prior art date
Application number
BRPI0112986A
Other languages
English (en)
Other versions
BR0112986A (pt
BR0112986B1 (pt
Inventor
Fromentin Claude
Alan Rowlands David
Aszodi Jozsef
Lampilas Maxime
Original Assignee
Astra Zeneca Holding France
Aventis Pharma Sa
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8853181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0112986(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Zeneca Holding France, Aventis Pharma Sa, Novexel filed Critical Astra Zeneca Holding France
Publication of BR0112986A publication Critical patent/BR0112986A/pt
Publication of BR0112986B1 publication Critical patent/BR0112986B1/pt
Publication of BRPI0112986B8 publication Critical patent/BRPI0112986B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"compostos azabicíclicos, o respectivo preparo e a respectiva utilização como medicamentos, notadamente como antibacteriano". a invenção se refere aos novos compostos heterocíclicos de fórmula geral (i), e seus sais com uma base ou um ácido. a invenção se refere igualmente a um processo para o preparo desses compostos, assim como sua utilização como medicamentos, notadamente como agentes anti-bacterianos.
BRPI0112986A 2000-08-01 2001-07-24 compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos BRPI0112986B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0010121A FR2812635B1 (fr) 2000-08-01 2000-08-01 Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR0010121 2000-08-01
PCT/FR2001/002418 WO2002010172A1 (fr) 2000-08-01 2001-07-24 Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Publications (3)

Publication Number Publication Date
BR0112986A BR0112986A (pt) 2003-07-08
BR0112986B1 BR0112986B1 (pt) 2014-04-01
BRPI0112986B8 true BRPI0112986B8 (pt) 2021-05-25

Family

ID=8853181

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112986A BRPI0112986B8 (pt) 2000-08-01 2001-07-24 compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos

Country Status (42)

Country Link
US (5) US7112592B2 (pt)
EP (1) EP1307457B1 (pt)
JP (2) JP4515704B2 (pt)
KR (1) KR100632906B1 (pt)
CN (1) CN1289500C (pt)
AP (1) AP1614A (pt)
AR (1) AR031716A1 (pt)
AT (1) ATE263768T1 (pt)
AU (2) AU7990501A (pt)
BG (1) BG66094B1 (pt)
BR (1) BRPI0112986B8 (pt)
CA (1) CA2417475C (pt)
CR (1) CR6895A (pt)
CZ (1) CZ294956B6 (pt)
DE (1) DE60102702T2 (pt)
DK (1) DK1307457T3 (pt)
DZ (1) DZ3397A1 (pt)
EA (1) EA004920B1 (pt)
EC (1) ECSP034460A (pt)
EE (1) EE05183B1 (pt)
ES (1) ES2220793T3 (pt)
FR (1) FR2812635B1 (pt)
HK (1) HK1060356A1 (pt)
HR (1) HRP20030034B1 (pt)
HU (1) HU226889B1 (pt)
IL (2) IL154187A0 (pt)
MA (1) MA26938A1 (pt)
ME (2) MEP17108A (pt)
MX (1) MXPA03000881A (pt)
NO (1) NO324940B1 (pt)
NZ (1) NZ523707A (pt)
OA (1) OA12347A (pt)
PL (2) PL216028B1 (pt)
PT (1) PT1307457E (pt)
RS (1) RS50214B (pt)
SI (1) SI1307457T1 (pt)
SK (1) SK287597B6 (pt)
TR (1) TR200400859T4 (pt)
TW (1) TWI292401B (pt)
UA (1) UA73791C2 (pt)
WO (1) WO2002010172A1 (pt)
ZA (1) ZA200300676B (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) * 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
DK2308874T3 (da) 2005-12-07 2013-04-15 Basilea Pharmaceutica Ag Brokoblede monobactamer nyttige som beta-lactamase-inhibitorer
WO2008008502A1 (en) 2006-07-13 2008-01-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
WO2008039420A2 (en) * 2006-09-27 2008-04-03 Merck & Co., Inc. Novel inhibitors of beta-lactamase
AU2007309195A1 (en) * 2006-10-23 2008-05-02 Irm Llc Cathepsin proteases inhibitors
JPWO2008093737A1 (ja) 2007-01-31 2010-05-20 大日本住友製薬株式会社 アミド誘導体
FR2914923B1 (fr) * 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2422603T3 (es) 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
KR101800610B1 (ko) * 2008-01-18 2017-11-23 머크 샤프 앤드 돔 코포레이션 베타­락타마제 억제제
US8518934B2 (en) * 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
EP3260551A1 (en) 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
JP5903386B2 (ja) * 2010-12-22 2016-04-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 光学活性なジアザビシクロオクタン誘導体およびその製造法
RU2769076C2 (ru) * 2011-06-17 2022-03-28 Пфайзер Анти-Инфективз Аб Способ получения гетероциклических соединений, включая транс-7-оксо-6-(сульфокси)-1,6-диазабицикло[3.2.1]октан-2-карбоксамид и его соли
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
EP2872510B1 (en) * 2011-08-30 2016-11-23 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
US8969567B2 (en) 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
BR112014003476A2 (pt) * 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PL2857401T3 (pl) 2012-05-30 2020-02-28 Meiji Seika Pharma Co., Ltd. NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
JPWO2014069351A1 (ja) 2012-11-01 2016-09-08 株式会社カネカ 光学活性二環式ウレア化合物の製造方法
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
JP6476110B2 (ja) 2013-02-19 2019-02-27 株式会社エーピーアイ コーポレーション Ｌ−リジン水酸化酵素およびそれを利用したヒドロキシ−ｌ−リジンの製造法およびヒドロキシ−ｌ−ピペコリン酸の製造法
CN105164132A (zh) * 2013-03-08 2015-12-16 沃克哈特有限公司 (2s,5r)-6-苄氧基-7-氧代-1,6-二氮杂-双环[3.2.1]辛烷-2-羧酸钠及其制备方法
NZ711326A (en) * 2013-03-08 2016-06-24 Wockhardt Ltd A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
MX362348B (es) * 2013-06-10 2019-01-11 Merck Sharp & Dohme Preparacion de 4-((1r,2s,5r)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[ 3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de ter-butilo.
SG11201602256UA (en) 2013-09-24 2016-04-28 Meiji Seika Pharma Co Ltd Production method for diazabicyclooctane derivative and intermediary body thereof
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
CA3110803C (en) 2013-10-08 2022-09-27 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015052682A1 (en) 2013-10-11 2015-04-16 Wockhardt Limited Nitrogen containing compounds and their use
WO2015112441A1 (en) 2014-01-22 2015-07-30 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
US9839642B2 (en) 2014-05-09 2017-12-12 Merck Sharp & Dohme Corp. Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
US9968593B2 (en) 2014-11-17 2018-05-15 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
US10053460B2 (en) 2014-12-02 2018-08-21 Merck Sharp & Dohme Corp. Process for the preparation of tert-butyl 4-((2S ,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
BR112017010445B8 (pt) 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
US10667737B2 (en) 2015-03-23 2020-06-02 International Business Machines Corporation Monitoring a person for indications of a brain injury
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN107580595B (zh) 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
WO2016206101A1 (en) 2015-06-26 2016-12-29 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
WO2017002087A1 (en) 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002086A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
US10265326B2 (en) 2015-08-10 2019-04-23 Sandoz Ag Form C of avibactam sodium
WO2017037607A1 (en) 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
JP2018515481A (ja) 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー，リミティド β−ラクタマーゼ阻害剤とその利用
CN107532185B (zh) 2015-10-02 2023-01-06 株式会社Api 羟基-l-哌可酸的制造方法
TW201725205A (zh) 2015-10-02 2017-07-16 樂高化學生物科學股份有限公司 用於抑制β-內醯胺酶之組合物及方法
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
CN106749242B (zh) * 2015-11-23 2021-04-02 上海医药工业研究院 阿维巴坦中间体的制备方法
WO2017136254A1 (en) 2016-02-04 2017-08-10 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN105753867B (zh) * 2016-03-24 2018-03-27 齐鲁制药有限公司 一种改进的阿维巴坦钠中间体化合物的制备方法
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
KR102482826B1 (ko) * 2016-08-26 2022-12-28 산도즈 아게 아비박탐 유리 산
PT3512851T (pt) 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
US20200017496A1 (en) * 2017-02-06 2020-01-16 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
MY201377A (en) 2017-05-08 2024-02-21 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
WO2019018186A1 (en) 2017-07-17 2019-01-24 Merck Sharp & Dohme Corp. METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE
EP3676247B8 (en) 2017-10-02 2023-04-12 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
JP7289836B2 (ja) 2017-11-23 2023-06-12 エフ． ホフマン－ラ ロシュ アーゲー プロリンヒドロキシラーゼ、ならびにそれに伴う使用、方法および生成物
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2020072442A1 (en) 2018-10-01 2020-04-09 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
WO2020185729A1 (en) 2019-03-12 2020-09-17 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
WO2020219258A1 (en) 2019-04-25 2020-10-29 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
CN110078728B (zh) * 2019-05-23 2020-10-23 江西富祥药业股份有限公司 一种阿维巴坦中间体、制备方法及其应用
WO2021106864A1 (en) * 2019-11-25 2021-06-03 Eisai R&D Management Co., Ltd. Process for the preparation of producing pyrazolo[1,5-a] pyrimidine derivatives
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939678B1 (pt) * 1968-05-06 1974-10-28
US4024147A (en) * 1972-06-30 1977-05-17 John Wyeth & Brother Limited Heterocyclic compounds
US4049821A (en) * 1976-05-12 1977-09-20 A. H. Robins Company, Inc. Method of treating allergy
EP0260057A3 (en) * 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
JPS63119471A (ja) * 1986-09-02 1988-05-24 ザ・ユニバーシテイ・オブ・メルボルン ２−オキソ−４−カルボキシ−ピリミジン
AU699465B2 (en) * 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
TW358097B (en) * 1996-05-24 1999-05-11 Hoffmann La Roche Beta-lactams and their process and pharmaceutical compositions
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
BR9811093A (pt) * 1997-02-10 2000-07-18 Pfizer Prod Inc Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo)
US6060585A (en) * 1997-03-04 2000-05-09 Wisconsin Alumni Research Foundation β-polypeptide foldamers of well-defined secondary structure
KR100207096B1 (ko) * 1997-07-08 1999-07-15 이명환 시사프라이드의 제조 방법
CN1305454A (zh) * 1998-04-20 2001-07-25 藤泽药品工业株式会社 作为cgmp－磷酸二酯酶抑制剂的邻氨基苯甲酸衍生物
GB9817029D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
FR2784682B1 (fr) * 1998-10-15 2002-12-06 Hoechst Marion Roussel Inc Nouveaux derives 2-halogene de 5-0-desosaminylerythronolide a, leur procede de preparation et leur application comme medicaments
US6635657B1 (en) * 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
HUP0105437A3 (en) * 1999-01-02 2003-03-28 Aventis Pharma Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Also Published As

Publication number Publication date
US7112592B2 (en) 2006-09-26
DE60102702T2 (de) 2005-04-07
RS50214B (sr) 2009-07-15
AU7990501A (en) 2002-02-13
EE05183B1 (et) 2009-06-15
DK1307457T3 (da) 2004-08-09
BR0112986A (pt) 2003-07-08
WO2002010172A1 (fr) 2002-02-07
TWI292401B (en) 2008-01-11
UA73791C2 (uk) 2005-09-15
NO324940B1 (no) 2008-01-07
NO20030494D0 (no) 2003-01-31
PL216028B1 (pl) 2014-02-28
DZ3397A1 (fr) 2002-02-07
ME00060B (me) 2010-06-10
SI1307457T1 (en) 2004-08-31
CZ294956B6 (cs) 2005-04-13
BG107497A (bg) 2003-09-30
JP2004505088A (ja) 2004-02-19
PL234468B1 (pl) 2020-02-28
MEP17108A (en) 2010-06-10
JP2010138206A (ja) 2010-06-24
HUP0302943A3 (en) 2007-08-28
YU6303A (sh) 2006-03-03
ZA200300676B (en) 2004-05-10
PT1307457E (pt) 2004-08-31
US7638529B2 (en) 2009-12-29
US7732610B2 (en) 2010-06-08
EA200300211A1 (ru) 2003-06-26
US20030199541A1 (en) 2003-10-23
CN1289500C (zh) 2006-12-13
CZ2003223A3 (cs) 2003-08-13
CN1468242A (zh) 2004-01-14
US8178554B2 (en) 2012-05-15
CA2417475A1 (fr) 2002-02-07
FR2812635A1 (fr) 2002-02-08
HRP20030034A2 (en) 2004-02-29
PL401469A1 (pl) 2013-02-04
MXPA03000881A (es) 2003-06-06
OA12347A (fr) 2006-05-15
BG66094B1 (bg) 2011-04-29
HU226889B1 (en) 2010-01-28
HK1060356A1 (en) 2004-08-06
AP1614A (en) 2006-05-21
US20060046995A1 (en) 2006-03-02
SK1052003A3 (en) 2003-11-04
FR2812635B1 (fr) 2002-10-11
BR0112986B1 (pt) 2014-04-01
ECSP034460A (es) 2003-03-10
EP1307457B1 (fr) 2004-04-07
AR031716A1 (es) 2003-10-01
KR100632906B1 (ko) 2006-10-13
IL154187A (en) 2009-02-11
KR20030019642A (ko) 2003-03-06
MA26938A1 (fr) 2004-12-20
NZ523707A (en) 2005-02-25
EP1307457A1 (fr) 2003-05-07
AU2001279905B2 (en) 2005-12-08
DE60102702D1 (de) 2004-05-13
HRP20030034B1 (en) 2011-03-31
US20110021772A1 (en) 2011-01-27
TR200400859T4 (tr) 2004-06-21
IL154187A0 (en) 2003-07-31
CR6895A (es) 2007-07-12
JP4515704B2 (ja) 2010-08-04
US20060189652A1 (en) 2006-08-24
HUP0302943A2 (hu) 2003-12-29
SK287597B6 (sk) 2011-03-04
NO20030494L (no) 2003-03-28
CA2417475C (en) 2010-04-20
ES2220793T3 (es) 2004-12-16
AP2003002726A0 (en) 2003-06-30
PL365162A1 (en) 2004-12-27
EA004920B1 (ru) 2004-10-28
EE200300046A (et) 2004-10-15
ATE263768T1 (de) 2004-04-15
US20110213147A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BRPI0509368A (pt) antagonistas cgrp selecionados, processo para a sua fabricação bem como seu uso como medicamento
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BRPI0412291A (pt) antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
BRPI0407387A (pt) Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
BRPI0109200B8 (pt) compostos e composições farmacêuticas
BR9912188A (pt) Derivados de 1,1-dióxido de benzo (b) tiepina, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0309242A (pt) Derivados de acil-4-carboxifenil-uréia, processo para a sua preparação e sua aplicação
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BRPI0413469A (pt) derivados de piperazina para o tratamento de infecções por hiv
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0017063A (pt) Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR0015322A (pt) Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVEXEL (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA SA

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/04/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved
B25A Requested transfer of rights approved
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/07/2021